CEL-SCI Corp (CVM)vsJohnson & Johnson (JNJ)
CVM
CEL-SCI Corp
$1.27
-10.46%
HEALTHCARE · Cap: $19.40M
JNJ
Johnson & Johnson
$259.34
-1.41%
HEALTHCARE · Cap: $613.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 337401847% more annual revenue ($96.36B vs $28,560). JNJ leads profitability with a 21.8% profit margin vs 0.0%. CVM appears more attractively valued with a PEG of 1.12. JNJ earns a higher WallStSmart Score of 57/100 (C).
CVM
Avoid27
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CVM
The strongest argument for CVM centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CVM
The primary concerns for CVM are EPS Growth, Market Cap, Profit Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CVM profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
CVM carries more volatility with a beta of 0.60 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 27/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CEL-SCI Corp
HEALTHCARE · BIOTECHNOLOGY · USA
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?